Skip to content

Effect evaluation and related mechanism research on different stages of IgA nephropathy treated by supplementing Qi, nourishing Yin and removing blood stasis

Effect evaluation and related mechanism research on different stages of IgA nephropathy treated by supplementing Qi, nourishing Yin and removing blood stasis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004291
Enrollment
Unknown
Registered
2021-01-19
Start date
2021-03-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgAN

Interventions

Sponsors

Zhejiang Provincal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. In line with Western medicine IgA nephropathy and renal function in line with the diagnostic criteria of CKD stage 1-4; 2. It conforms to the diagnostic criteria of TCM syndrome differentiation; 3. Patients are between 18 and 75 years of age, regardless of gender; 4. Infection, acidosis, electrolyte disturbance and hypertension have been well controlled; 5. No other organ function failure; 6. Have good compliance, have not participated in other clinical trials in recent half a year; 7. Informed and willing to accept clinical investigators.

Exclusion criteria

Exclusion criteria: 1. People who are allergic or allergic to known ingredients of the study drug; 2. Patients diagnosed with acute renal failure, and patients undergoing hemodialysis or peritoneal dialysis; 3. Patients with serious damage to the heart, liver, lung and other organs, or patients with wasting diseases such as malignant tumor or active tuberculosis; 4. Patients with gastrointestinal bleeding, or need to take other types of Chinese medicine during the test; 5. Those who do not cooperate with treatment; 6. Recent history of surgery; 7. Pregnant and lactating women; 8. Participants considered inappropriate by the investigator to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
Ang(1-7);ACE II;24-hour urinary protein quantity;Anti-NADPH oxidase 4;AOPPs;ACE;Glutathione peroxidase;ACE2;MDA;

Countries

China

Contacts

Public ContactLu Keda

Zhejiang Provincal Hospital of traditional Chinese medicine

lukedaq@126.com+86 13757175879

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026